Summary of Key Points
Aid Biotech, a private company specializing in tumor gene testing reagents, is about to change its owner. Forward Investment from Hong Kong has sold 20% of its shares to a subsidiary of Sinopharm Group for a total of RMB 1.654 billion. As a result, Aid Biotech will no longer be a private company but will become a state-owned enterprise (with Sinopharm Group as the actual controller). Aid Biotech’s strengths include a comprehensive product portfolio (35 types of tumor testing reagents in China, many of which are exclusive) and stable profits (a 40% increase in net profit by 2025). However, the industry is facing strict regulatory measures, making it more crucial to gain access to hospital sales channels. Sinopharm Group has been actively acquiring companies recently (such as Pailin Biotech and Shandong Yaobo). This acquisition of Aid Biotech aims to complete its large health industry chain transition from primarily selling drugs to also manufacturing products.
Transaction Details: RMB 1.654 Billion for 20% of Shares, Aid Biotech Becomes a State-Owned Enterprise
The original controlling shareholder of Aid Biotech was Forward Investment from Hong Kong. This time, it sold 78.02 million shares (representing 20% of the company) to the Science and Technology Innovation Research Institute under Sinopharm Group for RMB 21.2 per share, totaling RMB 1.654 billion. After the transaction, the Science and Technology Innovation Research Institute will become the controlling shareholder of Aid Biotech, and since Sinopharm Group owns 100% of the institute, Aid Biotech will be under the control of a state-owned enterprise.
Why Did Sinopharm Choose Aid Biotech? Strong Products and Stable Profits Make It an Industry Leader
Aid Biotech’s core business is tumor gene testing reagents. It has two significant advantages:
1. Comprehensive Product Portfolio: As of 2025, it offers the largest number of approved tumor testing products in China (35 types), many of which are exclusive to the company.
2. Stable Profits Despite Industry Challenges: Despite the pressure of medical insurance cost controls on the in vitro diagnostic industry, Aid Biotech’s net profit is expected to increase by 40% by 2025, mainly because its tumor gene testing segment has not been affected by national centralized procurement initiatives that drive down prices. These strengths have made it an attractive target for Sinopharm.
Industry Changes: Strict Regulations Make Hospital Access Crucial
The tumor gene testing industry is undergoing significant changes:
1. Stricter Regulations on External Testing: Hospitals were previously allowed to send samples for testing to third-party institutions, but now health authorities in many regions are strictly regulating such practices to ensure compliance.
2. Increased Importance of In-Hospital Sales: Policies require companies to sell reagents directly to hospitals; otherwise, they will lose business opportunities. This poses a challenge for Aid Biotech, which needs more hospital distribution channels, and Sinopharm can help with this.
Sinopharm’s Strategic Acquisitions: Moving from Drug Selling to Integrated Manufacturing
Sinopharm Group has traditionally made its money by selling drugs. With the new leadership (Bai Zhongquan taking over from Liu Jingzhen), it has been actively acquiring listed companies:
- Planning to acquire Pailin Biotech for RMB 4.7 billion to become China’s largest blood product company.
- Seeking control of Shandong Yaobo to enter the pharmaceutical materials industry.
- The acquisition of Aid Biotech complements its tumor testing capabilities.
These acquisitions are part of Sinopharm’s strategy to transform from a company mainly focused on drug sales to one that also manufactures drugs, reagents, and materials, aiming to build a comprehensive large health industry chain.
A Win-Win Situation for Both Parties
For Aid Biotech, Sinopharm’s extensive distribution network in Asia will enable it to sell its reagents to 700,000 hospitals and pharmacies, solving the issue of difficult access to hospital markets. For Sinopharm, Aid Biotech’s tumor testing technology will enhance its industry chain, bringing it one step closer to its goal of becoming a comprehensive large health company.
In summary, this acquisition is a mutually beneficial arrangement: Aid Biotech gains access to a larger market through Sinopharm’s channels, while Sinopharm strengthens its industrial capabilities with Aid Biotech’s technology, jointly advancing towards becoming a leading player in the entire health industry chain.